Literature DB >> 15775848

Antiangiogenesis cocktails - stirred or shaken?

Sara M Mariani1.   

Abstract

Mesh：

Substances：

Year:  2004        PMID： 15775848      PMCID： PMC1480579     

Source DB:  PubMed          Journal:  MedGenMed        ISSN： 1531-0132


× No keyword cloud information.
  28 in total

Review 1.  PDGF receptors as cancer drug targets.

Authors:  Kristian Pietras; Tobias Sjöblom; Kristofer Rubin; Carl-Henrik Heldin; Arne Ostman
Journal:  Cancer Cell       Date:  2003-05       Impact factor: 31.743

Review 2.  Angiogenesis inhibitors: a new class of drugs.

Authors:  Judah Folkman
Journal:  Cancer Biol Ther       Date:  2003 Jul-Aug       Impact factor: 4.742

Review 3.  Tyrosine kinases as targets in cancer therapy - successes and failures.

Authors:  Peter Traxler
Journal:  Expert Opin Ther Targets       Date:  2003-04       Impact factor: 6.902

4.  AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.

Authors:  Peter Traxler; Peter R Allegrini; Ralf Brandt; Josef Brueggen; Robert Cozens; Doriano Fabbro; Konstantina Grosios; Heidi A Lane; Paul McSheehy; Jürgen Mestan; Thomas Meyer; Careen Tang; Markus Wartmann; Jeanette Wood; Giorgio Caravatti
Journal:  Cancer Res       Date:  2004-07-15       Impact factor: 12.701

5.  Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors.

Authors:  Gabriele Bergers; Steven Song; Nicole Meyer-Morse; Emily Bergsland; Douglas Hanahan
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

Review 6.  Role of angiogenesis in tumor growth and metastasis.

Authors:  Judah Folkman
Journal:  Semin Oncol       Date:  2002-12       Impact factor: 4.929

7.  Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy.

Authors:  Kristian Pietras; Kristofer Rubin; Tobias Sjöblom; Elisabeth Buchdunger; Mats Sjöquist; Carl-Henrik Heldin; Arne Ostman
Journal:  Cancer Res       Date:  2002-10-01       Impact factor: 12.701

8.  Angiogenic factors reconstitute hematopoiesis by recruiting stem cells from bone marrow microenvironment.

Authors:  Shahin Rafii; Scott Avecilla; Sergey Shmelkov; Koji Shido; Rafael Tejada; Malcolm A S Moore; Beate Heissig; Koichi Hattori
Journal:  Ann N Y Acad Sci       Date:  2003-05       Impact factor: 5.691

9.  Regression of established tumors and metastases by potent vascular endothelial growth factor blockade.

Authors:  Jianzhong Huang; Jason S Frischer; Anna Serur; Angela Kadenhe; Akiko Yokoi; Kimberly W McCrudden; Tamara New; Kathleen O'Toole; Stephanie Zabski; John S Rudge; Jocelyn Holash; George D Yancopoulos; Darrell J Yamashiro; Jessica J Kandel
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-12       Impact factor: 11.205

10.  Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells.

Authors:  Francesco Bertolini; Saki Paul; Patrizia Mancuso; Silvia Monestiroli; Alberto Gobbi; Yuval Shaked; Robert S Kerbel
Journal:  Cancer Res       Date:  2003-08-01       Impact factor: 12.701
View more
  1 in total

1.  Beyond antiangiogenesis: vascular modulation as an anticancer therapy-a review.

Authors:  Bryan T Oronsky; Jan J Scicinski; Tony Reid; Susan Knox
Journal:  Transl Oncol       Date:  2012-06-01       Impact factor: 4.243
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.